DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on September 23, 2005; DOI: 10.1124/dmd.105.006163


0090-9556/05/3312-1911-1919$20.00
DMD 33:1911-1919, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.006163v1
33/12/1911    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ma, S.-F.
Right arrow Articles by Otagiri, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ma, S.-F.
Right arrow Articles by Otagiri, M.

HYDROLYSIS OF ANGIOTENSIN II RECEPTOR BLOCKER PRODRUG OLMESARTAN MEDOXOMIL BY HUMAN SERUM ALBUMIN AND IDENTIFICATION OF ITS CATALYTIC ACTIVE SITES

Shen-Feng Ma, Makoto Anraku, Yasunori Iwao, Keishi Yamasaki, Ulrich Kragh-Hansen, Noriyuki Yamaotsu, Shuichi Hirono, Toshihiko Ikeda, and Masaki Otagiri

Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan (S.-F.M., M.A., Y.I., M.O.); Department of Pharmacy, Miyazaki Medical College Hospital, Miyazaki, Japan (K.Y.); Department of Medical Biochemistry, University of Aarhus, Aarhus, Denmark (U.K.-H.); the School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan (N.Y., S.H.); and Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan (T.I.)

In the present study, we investigated the esterase-like activity of human serum albumin (HSA) and the mechanism by which it hydrolyzes, and thereby activates, olmesartan medoxomil (CS-866), a novel angiotensin II receptor antagonist. CS-866 has previously been shown to be rapidly hydrolyzed in serum in which HSA appeared to play the most important role in catalyzing the hydrolysis. We found that the hydrolysis of CS-866 by HSA followed Michaelis-Menten kinetics. Compared with the release of p-nitrophenol from p-nitrophenyl acetate (PNPA), CS-866 showed lower affinity to HSA and a lower catalytic rate of hydrolysis. Thermodynamic data indicated that PNPA has a smaller value of activation entropy ({Delta}S) than CS-866; consequently, PNPA is more reactive than CS-866. Ibuprofen and warfarin acted as competitive inhibitors of hydrolysis of CS-866, whereas dansyl-L-asparagine, n-butyl p-aminobenzoate, and diazepam did not. These findings suggest that the hydrolytic activity is associated to parts of site I and site II for ligand binding. All chemically modified HSA derivatives (Tyr-, Lys-, His-, and Trp-modifications) had significantly lower reactivity than native HSA; Lys-HSA and Trp-HSA had especially low reactivity. All the mutant HSAs tested (K199A, W214A, and Y411A) exhibited a significant decrease in reactivity, suggesting that Lys-199, Trp-214, and Tyr-411 play important roles in the hydrolysis. Results obtained using a computer docking model are in agreement with the experimental results, and strongly support the hypotheses that we derived from the experiments.


Address correspondence to: Professor Masaki Otagiri, Ph.D., Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862-0973, Japan. E-mail: otagirim{at}gpo.kumamotou.ac.jp







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.